Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
RMRCTV1
Study information
Scientific title
Acronym
Study hypothesis
Most renal transplants last between 8-10 years. The commonest cause of their failure is chronic allograft nephropathy - a pathological process where the kidney becomes fibrotic. This fibrosis is partly due to calcineurin inhibitors- the immunosupressants which protect the transplant.
The hypothesis to be tested in this study is that a combination of Myfortic and Sirolimus can be used to eliminate the calcineurin inhibitor Tacrolimus at 3 months post renal transplantation, thereby avoiding the long term detrimental effects of Tacrolimus on the development of renal allograft fibrosis.
Ethics approval
1. UK Medicines and Healthcare products Regulatory Agency (MHRA) approval obtained on 01/08/2007
2. The Central Office for Research Ethics Committees (COREC) approval pending minor changes to study literature as of 15/08/2007. (Nottingham Research Ethics Committee 2, 1 Standard Court, Park Row, Nottingham, NG1 6GN, UK). We will submit to local ethics review body (Leicester General Hospital) when central ethics approval has been gained.
Study design
A single-centre open randomised controlled trial.
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Not Specified
Patient information sheet
Condition
Renal transplantation
Intervention
Patients will be randomised to one of two drug regimens at three months post transplantation:
Regimen 1:
Tacrolimus: Twice daily oral doses as specified by attending physician to obtain trough levels of 5-15 ng/ml
Prednisolone: Once daily 20 mg oral dose. This will be reduced to 5 mg daily over two months.
Myfortic: Twice daily 720 mg oral dose
Regimen 2:
Sirolimus: Once daily oral dose as specified by attending physician to obtain trough levels of 10-15 ng/ml
Prednisolone: Once daily 20 mg oral dose. This will be reduced to 5 mg daily over two months.
Myfortic: Thrice daily 360 mg oral dose
Duration of interventions: 2 years
Intervention type
Other
Phase
Not Specified
Drug names
Primary outcome measures
1. Renal allograft fibrosis at 6 months post-trial entry
2. Renal function as measured by change in the slope of the eGFR over a period of at least 2 years (least squares method)
Secondary outcome measures
1. Change in cystatin C concentrations at 6 and 12 months compared to baseline
2. Incidence of biopsy proven acute rejection. The diagnosis and graded severity of acute renal allograft rejection will be made by employing the 1997 Banff criteria
3. Renal allograft profibrotic gene expression determined by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
4. Patient and graft survival at 6, 12 and 24 months post-trial entry
5. Comparison of blood pressure and the requirements for anti hypertensive therapy
6. Comparison of hyperlipidaemia (to include cholesterol, triglycerides, Low Density Lipoprotein [LDL] and High Density Lipoproteins [HDL]) and the requirement for treatment of elevated lipids
7. Proteinuria assessed by 24 hour urinary protein at 3, 6 and 12 months
8. Quality of life differences on the 36-item Short Form health survey (SF-36) at 6 and 12 months compared to baseline
Overall trial start date
01/10/2007
Overall trial end date
01/10/2009
Reason abandoned
Eligibility
Participant inclusion criteria
Patients will be eligible for the trial if all of the following criteria are met:
1. Age greater than or equal to 18 years
2. Patients receiving a primary or secondary renal allograft from a living related, living unrelated or heart-beating cadaveric donor
3. Patients with second transplants must have maintained their primary graft for at least six months after transplantation (with the exception of graft failure due to technical reasons)
4. Stable renal allograft function over the first 3 months post transplant
5. An absence of subclinical rejection on the 3 month protocol biopsy
6. A negative pregnancy test pre-protocol biopsy
7. Signed written informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
42
Participant exclusion criteria
Patients will not be eligible for the trial if any of the following criteria apply:
1. Kidney transplantation from a non heart-beating donor
2. Patients suffering an acute rejection episode in the first 3 months post transplant with a Banff classification of 1b or above
3. Sub-clinical rejection seen in the 3-month protocol biopsy
4. Proteinuria >500 mg/24 hours
5. Estimated Glomerular Filtration Rate (eGFR) <40 mls/min (Cockcroft-Gault formula)
6. Evidence of active systemic or localised major infection at study entry
7. Known hypersensitivity to Tacrolimus, macrolide antibiotics or Myfortic
8. Use of any investigational drug or treatments within 28 days before study entry
9. Known or suspected malignancy within five years before study entry
10. Any condition which in the opinion of the investigator makes the patient unsuitable for entry into the study
Recruitment start date
01/10/2007
Recruitment end date
01/10/2009
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Department of Renal Transplantation
Leicester
LE5 4PW
United Kingdom
Sponsor information
Organisation
University Hospitals of Leicester NHS Trust (UK)
Sponsor details
Leicester General Hospital
Gwendolen Road
Leicester
LE5 4PW
United Kingdom
+44 (0)116 258 4604
yashajohari@doctors.net.uk
Sponsor type
Government
Website
Funders
Funder type
Government
Funder name
University Hospitals of Leicester NHS Trust (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
Funding is also being sought from Wyeth Pharma and Novartis
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary